Skip Navigation

European Heart Journal 2003 24(20):1801-1803; doi:10.1016/j.ehj.2003.08.007
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Verheugt, F. W.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verheugt, F. W.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Combining glycoprotein blockers with fibrinolysis: a bold stroke?

Freek W.A. Verheugt*

Department of Cardiology, University Medical Center St Radboud, Nijmegen, The Netherlands

* Correspondence to: Freek W. A. Verheugt, MD, FESC, FACC, Professor of Cardiology, Heartcenter, 540 Department of Cardiology, P.0. Box 9101, University Medical Center St Radboud, Nijmegen, The Netherlands. Tel.: +31-24-3614220; Fax: +31-24-3540537
E-mail address: f.verheugt@cardio.umcn.nl

Received 19 August 2003; accepted 21 August 2003

The first 10% of the full text of this article appears below.

See doi:10.1016/j.ehj.2003.07.004for the article to which this editorial refers

For the future treatment of ST-elevation myocardial infarction, fibrinolytic therapy will be the most widely used therapy, because of its simplicity, worldwide availability and relatively low cost. In comparison to primary angioplasty, which will continuously be hampered by its limited availability and inherent time delay, fibrinolytic therapy has two major drawbacks: partial efficacy and a small, but significant risk of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, R.M. Califf, E.J. Topol, and for the GUSTO V Investigators
EHJ 2003 24: 1807-1814. [Abstract] [Full Text]